TAK-573 + bortezomib + dexamethasone

TAK-573 + bortezomib + dexamethasone is a combination therapy under investigation for relapsed or refractory multiple myeloma. TAK-573 is an engineered fusion protein (peptide-Fc fusion) that fuses a proprietary recombinant IgG1 Fc fragment with a modified human interleukin-15 (IL-15) molecule. TAK-573 is designed to stimulate the immune system by specifically expanding and activating natural killer (NK) cells and CD8+ cytotoxic T-cells, while limiting activation of regulatory T-cells. Bortezomib is a first-in-class proteasome inhibitor that inhibits the 26S proteasome, leading to apoptosis in malignant plasma cells. Dexamethasone is a synthetic glucocorticoid used for its anti-inflammatory and immunosuppressant effects, which also induce apoptosis in lymphoid cells. The combination leverages direct antitumor effects of bortezomib and dexamethasone, plus immune-mediated cytotoxicity stimulated by TAK-573, for synergistic treatment of multiple myeloma[6].